If children and adolescents suffer a relapse despite first-line therapy and intensive pretreatment, their chances of recovery have often not been good until now -- especially if the tumors were solid or brain tumors. Thanks to far-reaching developments in molecular biological genetic analysis and a large number of new so-called targeted drugs and immunotherapeutic therapy methods, we now have reason to hope that we will be able to help these children better in the future.
Patients with cancer (excluding most) and severe blood diseases can participate in clinical trials of the GPOH (Society for Pediatric Oncology and Hematology) with us and thus gain access to state-of-the-art diagnostic and therapeutic procedures. An overview of ongoing pediatric oncology studies, including numerous therapy optimization studies, is provided by the GPOH on its study portal.
The KiTZ Clinical Trial Unit also develops experimental phase I/II clinical trials as part of the translational KiTZ program to test new therapeutic approaches. With this individualized approach, the study unit assumes a pioneering role in Germany. The ongoing studies for children and adolescents with cancer at KiTZ are listed under the respective subheading of the entities.